Answers are grounded in this paper and cite their sources.
Retrospective cross-sectional study finds symptom onset before age 40 strongly correlates with hypercoagulability in livedoid vasculopathy, suggesting age-stratified screening guidelines.
Livedoid vasculopathy (LV) is a rare vaso-occlusive disorder characterized by reticular purpuric patches that may ulcerate and heal with atrophic porcelain-white scars, called atrophie blanche.1 LV can be due to venous insufficiency or prothrombotic states such as connective tissue disease, paraproteinemias, or hypercoagulability disorders, including antithrombin deficiency, protein C/S deficiency, Factor V Leiden mutation, prothrombin mutation, antiphospholipid antibody syndrome and others.2 Workup for an underlying hypercoagulable disorder is important because in certain cases, anticoagulation can lead to disease improvement.3 There are currently no standardized guidelines on hypercoagulability testing in LV, and comprehensive hypercoagulability testing can be costly. This is a retrospective cross-sectional study that examines the relationship between age at onset of LV and two common causes of LV: hypercoagulability and venous insufficiency. Patients included in the study were at least 18 years of age at UT Southwestern Medical Center and Parkland Hospital and had (1) either a biopsy- or clinically proven diagnosis of LV by a dermatologist and (2) ≥3 hypercoagulability tests performed. A clinical diagnosis of LV was defined by having ≥2 characteristic clinical findings including livedo reticularis or racemosa, ulceration on the distal legs or atrophie blanche.4 Clinical examination findings and laboratory results were reviewed to determine whether patients had venous insufficiency or hypercoagulability-associated LV. Age of symptom onset was defined by the onset of cutaneous signs of disease, most commonly purpuric patches, livedo reticularis or racemosa and retiform purpura. Categorical variables were compared using χ2 test or Fisher's exact test, and continuous variables were compared using the Mann–Whitney U test between patients with hypercoagulability and venous insufficiency-associated LV. Patients were stratified based on age of symptom onset of 40 years because hereditary thrombophilia was found to be significantly higher among patients who first experienced a thrombosis under the age of 40.5 A two-sided p value of <0.05 was considered statistically significant. R, version 4.2.0, was used for all statistical analyses. Table 1 summarizes the demographics and clinical characteristics of our cohort. The mean age at symptom onset was 50.5 years (standard deviation, 14.1). Among 38 adult patients with LV, 24 (63.2%) were hypercoagulability-associated and 14 (36.8%) were venous insufficiency-associated. The most common abnormal hypercoagulability test results were antiphosphatidylserine antibody (42.9%, n = 21), antithrombin (38.9%, n = 18), lupus anticoagulant (31.3%, n = 16), protein C (28.6%, n = 21) and protein S (25.0%, n = 20; Table 2). Among the clinical findings of the 24 patients with hypercoagulability-associated LV, 19 (79.2%) had atrophie blanche, 3 (12.5%) had varicose veins, 13 (54.2%) had oedema, and 10 (41.7%) had venous stasis dermatitis. When stratified by age, patients with an age of symptom onset of younger than 40 years were significantly more likely to have hypercoagulability-associated LV than those 40 years or older (90.9% vs. 51.9%; p = 0.03). Patients with stasis-associated LV were more likely to have an age of LV onset of 40 years or older (92.9% vs. 7.1%). This study is limited by its retrospective design, small sample size due to the low incidence of LV, and lack of uniform hypercoagulability workup for each patient. To optimize patient resources and avoid unnecessary testing, the findings of this study suggest that providers consider the age of symptom onset in the workup of LV. Those younger than 40 years of age may benefit from hypercoagulability testing even if signs of venous insufficiency are present. Further studies are needed to determine whether certain demographic or clinical factors are associated with hypercoagulability in those 40 years and older. Conception or design of the work: Cristina Thomas. Data collection: Kim Le. Data analysis and interpretation: Kim Le and Cristina Thomas. Drafting the article: Kim Le. Critical revision of the article: Cristina Thomas. All authors discussed the results and contributed to the final manuscript. The authors declare no conflict of interest. Reviewed and approved by the University of Texas Southwestern Medical Institutional Review Board (STU-2021-0270). The data that support the findings of this study are available on request from the corresponding author.
No takes yet. Share an insight, caveat, or question.
Le et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: